# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to know quickly and plainly whether the spot on the scan is cancer, and what can be done **S**
- He has smoked for 35 years, has failed to stop twice on his own, and worries that stopping now is pointless **S**
- No doctor had offered him a lung scan before; he wants the same care anyone else would get, without delay **S**
- He wants to keep speaking to young people and to keep walking every morning **S**

## Your goals

- PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT. Target: 2026-05-26. Recorded outcome: PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan. **S**
- Stop smoking completely before treatment starts and stay stopped. Target: 2026-09-30. Recorded outcome: No cigarettes since day 1 of cycle 1, about four months; varenicline continued to complete 24 weeks. **S**
- Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher. Target: 2026-08-05. Recorded outcome: Three cycles on schedule; only a grade 1 rise in TSH, monitored without treatment. **S**
- Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle. Target: 2026-09-30. Recorded outcome: Thoracoscopic left upper lobectomy five weeks after cycle 3; R0; major pathologic response. **S**
- Back to walking 3 km most mornings by three months after surgery. Target: 2026-09-30. Recorded outcome: Walking 2 km a day six weeks after surgery and starting pulmonary rehabilitation. **S**

## What we agreed to do

- Referral to thoracic oncology: consultation within two weeks to review the screening CT, PET-CT and EBUS results with him and plan treatment. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Work-up of the Lung-RADS 4X nodule without delay: FDG PET-CT and brain MRI with contrast this week, then endobronchial ultrasound with systematic sampling of mediastinal and hilar nodes (at least stations 4R, 4L and 7, and any PET-avid node), with enough tissue for PD-L1 and comprehensive next-generation sequencing (EGFR, ALK, ROS1, BRAF, KRAS, MET exon 14, RET, NTRK, HER2) and plasma testing in parallel; nurse navigator to track each date. Guideline: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(10):962-970 (PMID 33687470) (2021); Mazzone PJ, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest 2021;160(5):e427-e494 (PMID 34270968) (2021); Lung CT Screening Reporting and Data System (Lung-RADS) v2022 (2022); Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013) **S**
- Tobacco treatment at every visit: brief advice, varenicline offered with a quit date, the Arizona quitline and counseling; stopping smoking improves outcomes even after a lung cancer diagnosis. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
- Equity safeguards: a nurse navigator, written results and next steps at each visit, transport and cost help offered, and time from scan to treatment tracked against the goal. Guideline: Aldrich MC, et al. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers. JAMA Oncol 2019;5(9):1318-1324 (PMID 31246249) (2019); Bach PB, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341(16):1198-1205 (PMID 10519898) (1999) **S**
- Distress and depression screening at each visit, plain information he can share, and advance care planning when he is ready. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026) **S**
- Chemoimmunotherapy before surgery: nivolumab 360 mg with carboplatin (AUC 5) and pemetrexed 500 mg/m2 every three weeks for three cycles, with folic acid, vitamin B12 and dexamethasone premedication, hepatitis B, hepatitis C and HIV tests first, and restaging CT before surgery. Guideline: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med 2022;386(21):1973-1985 (PMID 35403841) (2022) **S**
- Immune-related adverse event monitoring: TSH, free T4, liver tests, creatinine, glucose and blood count before each cycle, morning cortisol at baseline and before surgery, and a written list of warning symptoms with a 24-hour oncology line. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021) **S**
- Physiologic evaluation for lobectomy (spirometry and DLCO with predicted postoperative values) and prehabilitation: a pulmonary rehabilitation program during chemotherapy. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013) **S**
- Thoracoscopic left upper lobectomy with systematic mediastinal and hilar lymph node dissection after restaging shows response and no new disease. Guideline: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S (PMID 23649443) (2013) **S**
- After surgery: no further systemic therapy after a major pathologic response, by shared decision; history, examination and chest CT every six months for two to three years, then yearly low-dose CT; pulmonary rehabilitation after surgery; the KRAS G12C result kept on file for any recurrence. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Schneider BJ, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary. JCO Oncol Pract 2020;16(2):83-86 (PMID 32045555) (2020) **S**

## Follow-up

- 2026-05-11: New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment **S**
- 2026-05-26: Diagnosis of left upper lobe adenocarcinoma, stage IIB: thoracic oncology consultation, tumor board plan for chemoimmunotherapy before surgery, and start of varenicline **S**
- 2026-06-24: Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation **S**
- 2026-08-05: After three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation **S**
- 2026-09-30: Six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation **S**
- 2026-10-21: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
